{"id":"W4392014388","doi":"10.1016/j.esmoop.2024.102254","title":"A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Principia Biopharma; Loxo Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Astellas Pharma; Cancer Research UK; Seagen; MacroGenics; Ascentage Pharma; Menarini Group; F-star Therapeutics; Symphogen; Moderna; Pfizer; Innovent Biologics; Incyte; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; GlaxoSmithKline; Tizona Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Novartis Farmacéutica; Alexion Pharmaceuticals; Servier; Gilead Sciences; Sanofi; Helsinn Therapeutics; Amgen; Jounce Therapeutics; LAM Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Onyx Pharmaceuticals; Eli Lilly and Company","keywords":"Monoclonal antibody; Antibody; Solid tumor; Dosing; Cancer research; Medicine; Monoclonal; Internal medicine; Immunology; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00271279,0.001694759,0.001638942,0.0003995197,0.0006182669,0.001098674,0.0008606825,0.001135976,0.003746988],"category_scores_gemma":[0.000904439,0.0008489806,0.001367577,0.0003817769,0.0009543693,0.0009908458,0.000456155,0.004014508,0.001077718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001109228,"about_ca_system_score_gemma":0.002498332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001097311,"about_ca_topic_score_gemma":0.003213899,"domain_scores_codex":[0.9993846,0.00030253,0.00002153605,0.00009620055,0.00004929359,0.0001457276],"domain_scores_gemma":[0.9991793,0.0001207336,0.0001157199,0.0001008688,0.00005375413,0.0004295607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3964033,0.2282769,0.0161364,0.001382276,0.001637239,0.0008379912,0.0007157244,0.004317149,0.1817995,0.0006123655,0.01721456,0.1506666],"study_design_scores_gemma":[0.3224719,0.6325749,0.01702313,0.00003732479,0.0005011163,0.0006311544,0.00008689355,0.001045618,0.01707287,0.0002459343,0.008258962,0.00005021632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840943,0.001679364,0.00135408,0.000553501,0.0001680788,0.006381626,0.003424208,0.0001886633,0.002156091],"genre_scores_gemma":[0.978269,0.001806672,0.003490511,0.001212972,0.0001715001,0.004255581,0.006424292,0.00007267367,0.004296736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003746988,"threshold_uncertainty_score":0.01434678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01321478690260793,"score_gpt":0.3212640118319691,"score_spread":0.3080492249293612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}